CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Takara Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Takara Bio Inc
7-4-38, Noji-Higashi
Phone: +81 775656920p:+81 775656920 KUSATSU-SHI, SHG  525-0058  Japan Ticker: 49744974
This is a Subsidiary, click here for the Parent Company
Business Summary
Takara Bio Inc is a Japan-based company primarily engaged in businesses related to reagents, instruments, contract services and gene therapy. The Company has one business segment. The reagents, instruments and contract services business provides biotechnology-related research reagents, laboratory instruments and contract services to universities, research institutions and corporations, offering products in the fields of molecular and cell biology based on technologies including polymerase chain reaction (PCR), next-generation sequencing, genome editing and stem cells. The Company also promotes its contract development and manufacturing organization (CDMO) business, which includes contract manufacturing of regenerative medicine products and genetic analysis services. The gene therapy business advances the development of gene therapy drugs including genetically modified T-cell therapies and next-generation chimeric antigen receptor (CAR) technologies.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20253/31/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
3826 Laboratory analytical instruments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board KoichiNakao 63 6/24/2025 10/1/2007
President, Executive President, Chief Executive Officer, Representative Director TsuyoshiMiyamura 61 6/24/2025 6/1/2009
Vice President, Executive Vice President, Chief Financial Officer, Director YohHamaoka 62 6/24/2025 4/1/2004
12 additional Officers and Directors records available in full report.

Business Names
Business Name
4974
Cellectis AB
Rubicon Genomics, Inc.
Takara Bio Inc.
WaferGen Bio-systems, Inc.

General Information
Number of Employees: 1,779 (As of 3/31/2025)
Outstanding Shares: 120,415,487 (As of 9/30/2025)
Shareholders: 41,089
Stock Exchange: TYO
Fax Number: +81 775618007


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 6, 2025